



Human Chorionic Gonadotropin Formulation

3.5 09.04.2021 22126-00017 Date of first issue: 15.10.2014	Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
	3.5	09.04.2021	22126-00017	Date of first issue: 15.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Human Chorionic Gonadotropin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet

Company	:	Organon & Co. Shotton Lane NE23 3JU Cramlington NU - Great Britain
Telephone	:	44 1 670 59 30 00
E-mail address of person responsible for the SDS	:	EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

2.2

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATI	ON	(EC) No 1272	2/2008)
Reproductive toxicity, Categ	ory	1A	H360Fd: May damage fertility. Suspected of dam- aging the unborn child.
Specific target organ toxicity exposure, Category 1	′ - re	epeated	H372: Causes damage to organs through pro- longed or repeated exposure.
Label elements			
Labelling (REGULATION (I	EC)	No 1272/200	8)
Hazard pictograms	:		
Signal word	:	Danger	
Hazard statements	:	H360Fd	May damage fertility. Suspected of damaging

Hazard statements : H360Fd May damage fertility. Suspected of damaging the unborn child. H372 Causes damage to organs through prolonged or repeated exposure. Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.

according to Regulation (EC) No. 1907/2006



Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 22126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Gonadotropin, chorionic

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
Gonadotropin, chorionic	9002-61-3	Repr. 1A; H360Fd	>= 90 - <= 100
	232-660-2	STOT RE 1; H372	
		(Ovary)	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water.



Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 22126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
		Get medical a Wash clothing	aminated clothing and shoes. attention. g before reuse. lean shoes before reuse.
In case	e of eye contact	-	se well with water. attention if irritation develops and persists.
If swal	lowed	Get medical a	DO NOT induce vomiting. attention. thoroughly with water.
4.2 Most ir	nportant symptoms	and effects, both a	cute and delayed
Risks		child.	fertility. Suspected of damaging the unborn age to organs through prolonged or repeated
		Contact with	dust can cause mechanical irritation or drying of

4.3 Indication of any immediate medical attention and special treatment needed

the skin.

Dust contact with the eyes can lead to mechanical irritation.

	•	-
Treatment	:	Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media				
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical		
Unsuitable extinguishing media	:	None known.		
5.2 Special hazards arising from the substance or mixture				
Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.		
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx) Sulphur oxides		
5.3 Advice for firefighters Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.		

according to Regulation (EC) No. 1907/2006



Human Chorionic Gonadotropin Formulation

Versior 3.5	n Revision Date: 09.04.2021	SDS Number: 22126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014			
Sr od	ecific extinguishing meth- Is	cumstances an Use water spra	ng measures that are appropriate to local cir- d the surrounding environment. y to cool unopened containers. haged containers from fire area if it is safe to do			
SECT	ON 6: Accidental relea	se measures				
6.1 Personal precautions, protective equipment and emergency procedures						
Pe	ersonal precautions	Follow safe har	rotective equipment. Indling advice (see section 7) and personal pro- ent recommendations (see section 8).			
6.2 En	vironmental precautions					
Er	vironmental precautions	Prevent further Retain and disp	o the environment. leakage or spillage if safe to do so. lose of contaminated wash water. s should be advised if significant spillages ained.			
6.3 Me	thods and material for co	ntainment and clea	ning up			
M	ethods for cleaning up	tainer for dispos	cuum up spillage and collect in suitable con- sal. of dust in the air (i.e., clearing dust surfaces			

with compressed air).

mine which regulations are applicable.

certain local or national requirements.

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

Sections 13 and 15 of this SDS provide information regarding

6.4 Reference to other sections See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion.
	Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	: Do not get on skin or clothing.

according to Regulation (EC) No. 1907/2006



Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 22126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014		
Hygiene measures		Do not swallo Avoid contact Wash skin the Handle in acc practice, base sessment Keep containe Keep away fre Take precauti Do not eat, dr Take care to p environment. If exposure to flushing syste place. When to	Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the		
7.2 Cond	itions for safe storage,	including any inc	ompatibilities		
	uirements for storage s and containers		erly labelled containers. Store locked up. Keep Store in accordance with the particular national		
Advi	ce on common storage	: Do not store v Strong oxidizi Organic perov Explosives Gases			
7 2 Speed	ific and usa(s)				
-	i fic end use(s) cific use(s)	: No data availa	able		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Gonadotropin, chorionic	9002-61-3	TWA	OEB 4 (3 µg/m3)	Internal
		Wipe limit	25 µg/100 cm²	Internal

8.2 Exposure controls

Engineering measures

Minimize workplace exposure concentrations. Apply measures to prevent dust explosions.



according to Regulation (EC) No. 1907/2006

Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021		DS Number: 126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
		ned the	in a manner to pre equipment).	ducts, dust collectors, vessels, and pro- vent the escape of dust into the work area exhaust ventilation.
Perso	nal protective equipm	nent		
Eye pr	otection	:	Safety goggles	g personal protective equipment: I conform to BS EN 166
Hand p	protection			
Mat	terial	:	Chemical-resistar	t gloves
Rer	marks	:	on the concentrat stance and specif determined for the applications, we r chemicals of the a	protect hands against chemicals depending ion and quantity of the hazardous sub- ic to place of work. Breakthrough time is not e product. Change gloves often! For special ecommend clarifying the resistance to aforementioned protective gloves with the er. Wash hands before breaks and at the
Skin a	nd body protection	:	resistance data an potential. Skin contact must	e protective clothing based on chemical nd an assessment of the local exposure be avoided by using impervious protective aprons, boots, etc).
Respir	atory protection	:	If adequate local of sure assessment ommended guide	exhaust ventilation is not available or expo- demonstrates exposures outside the rec- lines, use respiratory protection.
Filter t	уре	:	Particulates type	

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	powder off-white odourless No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling	:	No data available
range Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available

according to Regulation (EC) No. 1907/2006



Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021		S Number: 26-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
	r explosion limit / Upper nability limit	:	No data available	
	r explosion limit / Lower nability limit	:	No data available	
Vapo	ur pressure	:	No data available)
Relat	ive vapour density	:	No data available	9
Relat	ive density	:	No data available	9
W Partit	bility(ies) ater solubility ion coefficient: n- ol/water	:	soluble No data available	9
	ignition temperature	:	No data available)
Deco	mposition temperature	:	No data available	9
Visco Vi	sity scosity, kinematic	:	No data available	9
Explo	sive properties	:	Not explosive	
Oxidi	zing properties	:	The substance o	r mixture is not classified as oxidizing.
9.2 Other	information			
Mole	cular weight	:	No data available	9
Partic	cle size	:	No data available	9

SECTION 10: Stability and reactivity

10.1 Reactivity Not classified as a reactivity haza	rd.
10.2 Chemical stability Stable under normal conditions.	
10.3 Possibility of hazardous reaction	ons
Hazardous reactions :	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid :	Heat, flames and sparks. Avoid dust formation.
10.5 Incompatible materials	
Materials to avoid :	Oxidizing agents
	7 / 12

according to Regulation (EC) No. 1907/2006



Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22126-00017	Date of first issue: 15.10.2014

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of : Inhalation exposure Skin conta

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Components:

Gonadotropin, chorionic:

Effects on fertility

: Test Type: Fertility Species: Rat Application Route: Intravenous injection Fertility: LOAEL: 8.89 mg/kg body weight Result: Effects on fertility

Test Type: Fertility Application Route: Intraperitoneal injection Fertility: LOAEL: 0.883 mg/kg body weight Result: Effects on fertility

Test Type: Fertility Species: Monkey Fertility: LOAEL: 0.224 mg/kg body weight



according to Regulation (EC) No. 1907/2006

Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 22126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014			
		Result: Effects or	fertility			
Effects on foetal develop- ment Reproductive toxicity - As- sessment		 Test Type: Embryo-foetal development Species: Hamster Application Route: Intraperitoneal injection Embryo-foetal toxicity: LOAEL: 60 mg/kg body weight Result: Embryo-foetal toxicity Positive evidence of adverse effects on sexual function and fertility from human epidemiological studies., Some evidence of adverse effects on development, based on animal experi- ments. 				

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

Gonadotropin, chorionic:

Target Organs Assessment	OvaryCauses damage to organs through prolonged or repeated
	exposure.

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Gonadotropin, chorionic:

Inhalation

: Target Organs: ovaries Symptoms: effects on menstruation, gynecomastia, Headache, mental depression, Irritability, restlessness, Fatigue

SECTION 12: Ecological information

12.1 Toxicity

No data available

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

according to Regulation (EC) No. 1907/2006



Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021		DS Number: 2126-00017	Date of last issue: 25.09.2020 Date of first issue: 15.10.2014
Asse	ssment	:	to be either persis	ixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 Othe	r adverse effects			
Prod	uct:			
Endo tial	crine disrupting poten-	:	ered to have ende REACH Article 57	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
SECTION	N 13: Disposal consi	dera	ations	

13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture



Human Chorionic Gonadotropin Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 22126-00017		last issue: 25.09.2020 first issue: 15.10.2014	
the ma	H - Restrictions on the rket and use of certain ations and articles (Anr		Not applicable		
REACH		ubstances of Very High	ı :	Not applicable	
	H - List of substances s	subject to authorisation	:	Not applicable	
Regula	,	9 on substances that d	le- :	Not applicable	
	tion (EU) 2019/1021 o	n persistent organic po	llu- :	Not applicable	
Regula ment a	tion (ÉC) No 649/2012	of the European Parlia ning the export and imp		Not applicable	
Seves	b III: Directive 2012/18/	EU of the European Pa	arliament	and of the Council on the control	l c

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.		
Full text of H-Statements			
H360Fd	May damage fertility. Suspected of damaging the unborn child.		
H372	Causes damage to organs through prolonged or repeated exposure.		
Full text of other abbreviations			
Repr. STOT RE	Reproductive toxicity Specific target organ toxicity - repeated exposure		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for



Human Chorionic Gonadotropin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 25.09.2020
3.5	09.04.2021	22126-00017	Date of first issue: 15.10.2014

the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Classification of the mixture:		Classification procedure:
Repr. 1A	H360Fd	Calculation method
STOT RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN